What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Australasian Leukaemia & Lymphoma Group - ALLG

Home
Australia
Melbourne, VIC
Australasian Leukaemia & Lymphoma Group - ALLG

For patients, this means an improved chance of cure, and better quality of life.

Since 1973 the ALLG has been pioneering life-changing blood cancer clinical trials, delivering innovative treatment options that transform the lives of those with blood cancer. The Australasian Leukaemia & Lymphoma Group (ALLG) is the only not-for-profit, collaborative clinical research group in Australia and New Zealand dedicated to finding new ways to treat blood cancers such as leukaemia, lymph

oma, myeloma and myelodysplastic syndromes. The ALLG membership includes more than 1,000 doctors, nurses, scientists and support staff across Australia and New Zealand, all of whom are looking for ways to better treat blood cancers through clinical research. By conducting national and international collaborative clinical trials at sites across Australia and New Zealand, ALLG researchers are helping to make new and more effective treatments available to people suffering from blood cancers.

21/04/2026

Today on , the ALLG is highlighting the impact of acute myeloid leukaemia (AML) on patients and carers through a powerful story from one of our trial participants, Ania.

Shared by her daughter Belinda, this story honours her mother’s journey with AML and Ania’s legacy in advocating for clinical trial research to help others.

Over 900 Australians are diagnosed every year with AML, a rare and aggressive blood cancer. Sadly, only 22% of people diagnosed with AML will survive 5 years after diagnosis. There is a great unmet need for better treatments that deliver better outcomes and save lives.

Behind every AML diagnosis is a family, a story, and a legacy that inspires ALLG researchers to progress vital research into new AML treatments. Ania’s story is a reminder of the importance of clinical trials and research in improving outcomes for people affected by blood cancer.

ALLG is the only not-for-profit blood cancer clinical trial research group in Australasia, with over 1400+ researchers and clinical trial professionals dedicated to research into Better treatments…Better lives.

Read the full story and learn more about the impact of AML and Ania’s legacy - https://www.allg.org.au/aml-awareness-day-2026-mums-legacy/. You can help ALLG to continue delivering life-saving research for AML patients by donating today - https://www.allg.org.au/support-us/make-a-donation/.

14/04/2026

Our ALLG Scientific Meetings bring together blood cancer researchers, clinicians and experts twice a year to generate new research concepts and clinical trials that improve treatments, patient outcomes and quality of life.

The upcoming May Scientific Meeting features a range of local and international speakers discussing the latest research in the field and cutting-edge clinical trials that are delivering Better treatments...Better lives to patients living with blood cancer.

To find out more about ALLG’s research, visit allg.org.au.

09/04/2026

ALLG’s National Blood Cancer Registry (NBCR) is a vital piece of research infrastructure. Not only does it provide a pathway for people with blood cancer to access lifesaving ALLG clinical trials, but it also acts as a trusted source of real-world patient data, enabling researchers to better understand risk factors and causes for blood cancers such as leukaemia, lymphoma, and myeloma.

There are no screening tests or preventative measures available for blood cancer. The NBCR provides an invaluable service to the nearly 20,000 Australians diagnosed annually with a blood cancer by increasing their access to trials, and powering new, vital research into better treatments and care.

Donate now to support the National Blood Cancer Registry, so our Australian and New Zealand research leaders can deliver future breakthroughs through blood cancer trials that create Better treatments…Better lives.

Click here to learn more and support ALLG’s registry today: https://www.allg.org.au/clinical-trials-research/national-blood-cancer-registry/.

07/04/2026

Every year, 900 adolescents and young adults are diagnosed with cancer in Australia. They immediately face life-altering challenges as they navigate diagnosis, treatment and recovery.

Throughout April, our friends at Canteen Australia are marking Youth Cancer Awareness Month and shining a spotlight on the unique challenges faced by young people impacted by cancer.

ALLG’s researchers continue to drive meaningful progress in blood cancer research in adolescent and young adult (AYA) patients. Led by Associate Professor Matthew Greenwood, our ALL09 SUBLIME clinical trial into acute lymphoblastic leukaemia (ALL) in AYA patients was recently published in prestigious medical journal HemaSphere.

The ALL09 SUBLIME trial results showed that replacing chemotherapy with a targeted immunotherapy called blinatumomab resulted in higher rates of cancer remission and overall survival in young adults with ALL, with less side effects, paving the way to adopt this treatment worldwide.

The ALL09 trial was funded by Canteen through the Australian Young Cancer Patient Clinical Trials Initiative, supported by the Australian Government’s Medical Research Future Fund (MRFF).

This important study highlights how clinical trial research is vital to generate high-quality evidence to transform treatments and care for young Australians. To find out more about ALLG’s clinical trial research, visit allg.org.au.

02/04/2026

Stay updated on blood cancer clinical trial research with the latest updates and insights!

ALLG’s news page features the latest developments, including new trials, research highlights and expert insights from scientists and clinicians shaping the future of blood cancer care and treatment. Visit https://www.allg.org.au/news/ for more. You can also subscribe to our ALLG Newsletter, delivered quarterly - https://www.allg.org.au/subscribe-to-allg-news/.

31/03/2026

ALLG is delighted to launch the 2027 ALLG HSANZ Clinical Trials Fellowship for outstanding early career blood cancer researchers.

The ALLG Fellowship is designed to support the next generation of blood cancer researchers to drive better treatments for patients with leukaemia, lymphoma, myeloma and other blood cancers. The 12-month Fellowship Program will be awarded to an early career haematologist and provides $70,000 in funding for a research project into blood cancer.

Now in its third year, our new 2027 Fellow will join Dr Arina Martynchyk (2025 Fellow) and Dr Safia Belbachir (2026 Fellow) in pursuing new, innovative research that helps delivery better treatments and outcomes for people with blood cancer.

ALLG CEO, Delaine Smith, said “ALLG is proud to support this Fellowship that is helping accelerate the impact for patients through quality clinical trial research.”

For more information about the Fellowship Program, or to support this exciting initiative, visit: https://www.allg.org.au/support-us/our-campaigns/.

26/03/2026

ALLG is advancing blood cancer treatments and care through collaboration and innovation.

Our ALLG May Scientific Meeting brings together clinicians, researchers, scientists and clinical trial professionals from across Australia and New Zealand to share research breakthroughs, develop new clinical trials and drive the next generations of treatments for people with blood cancer.

Translating cutting-edge research into real-world impact, ALLG Scientific Meetings play a vital role in improving survival and quality of life for people with leukaemia, lymphoma and myeloma.

Learn more about the ALLG and our mission to create Better treatments…Better lives - allg.org.au.

24/03/2026

We are proud to share that 100 patients have now received access to innovative new treatments through ALLG’s AMLM26 INTERCEPT platform.

AMLM26 is a world-first, multi adaptive platform trial for people with acute myeloid leukaemia (AML). Using advanced molecular monitoring to detect early signs of AML, the trial aims to prevent relapse and keep patients in remission longer. AMLM26’s precision, targeted therapy approach has the potential to improve survival outcomes and quality of life in this rare and aggressive leukaemia.

The AMLM26 INTERCEPT trial now has five treatment arms open to AML patients, enabling access to innovative new therapies. The trial’s adaptive approach enables patients to rotate between treatment arms when their AML disease markers change, ensuring earlier, personalised adaptive care and better outcomes.

Clinical trials like AMLM26 are only possible because of sustained investment in blood cancer research. Philanthropic support helps to maintain the high-quality and complex infrastructure required to deliver adaptive platform trials and therapies to patients. To learn more about AMLM26 and how you can support clinical trial research, visit https://tinyurl.com/2x3ud5t3.

20/03/2026

At the ALLG, every clinical trial and research project is designed and conducted with patients’ lived experience and outcomes front of mind. From research to improve treatments and provide better survival, to enhancing quality of life for people with blood cancer - ALLG ensures that patient need and experiences guide every step of our clinical trials.

At ALLG, we work closely with clinical trial sites and participants, ensuring that patients’ needs are prioritised from the first visit to the final follow-up. Our Consumer Representative Panel ensures that blood cancer patients have a voice in research priorities, trial design and implementation.

By fostering inclusive, respectful collaboration between researchers, clinicians and patients, we deliver high-quality research that changes practice and impacts people’s lives for the better.

Discover how we keep patients at the centre of all we do - https://www.allg.org.au/putting-patients-at-the-centre-of-clinical-trials/.

18/03/2026

This March, our friends at the Leukaemia Foundation are taking part in the World’s Greatest Shave. This vital campaign helps fund support for the 53 Australians diagnosed with blood cancer every day, as well as the 140,000 families currently living with blood cancer across the country. To join in, visit worldsgreatestshave.com.

These confronting figures inspire ALLG and our researchers to continue advancing clinical trial research to develop better treatments — and ultimately, find a cure for blood cancer. To learn more about ALLG’s impact, visit allg.org.au.

12/03/2026

Applications for the 2026 Anne Lenton Memorial Scholarship & Janey Stone Research Award are now open!

These awards are offered exclusively to ALLG Associate Members, designed to promote the professional development and upskilling of the trial coordinators, research nurses and scientists who support ALLG clinical trials and correlative research. The ALLG Awards recognise the important contributions these vital roles make to our clinical trial teams.

The Anne Lenton Memoria Scholarship offers up to $5,000 in funding for a 12 month project, and the Janey Stone Research Award up to $10,000 in funding over a maximum of two years. The focus of both Awards is for research and/or projects that ultimately benefit knowledge and clinical trial processes.

For more information on the ALLG Awards and to apply online, log into the ALLG Member Dashboard at allg.org.au/member-area/scholarships-awards.

Applications close 31 July 2026.

11/03/2026

Every year, thousands of Australians and New Zealanders are diagnosed with blood cancers like leukaemia, lymphoma and myeloma. Research is the key to better treatments, longer survival and ultimately, a cure.

This is why the work of ALLG is important. Through clinical trials and medical research, we are delivering innovative, effective and less toxic treatments to people with blood cancer.

As the only not-for-profit blood cancer clinical trial research group in Australasia, this life-saving research depends on the support of people just like you. Your donation to ALLG will:

- Fund critical blood cancer clinical trials & research
- Support expert researchers to develop better treatments
- Give thousands of patients access to treatments not yet available

Every contribution helps drive our research for Better treatments...Better lives - allg.org.au.

Address

Ground Floor, 35 Elizabeth Street
Melbourne, VIC
3121

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Website

https://www.allg.org.au/support-us/make-a-donation/

Alerts

Be the first to know and let us send you an email when Australasian Leukaemia & Lymphoma Group - ALLG posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Australasian Leukaemia & Lymphoma Group - ALLG:

Shortcuts

Featured

Heidelberg Dermatology
5 Burgundy Street, Heidelberg

Want your practice to be the top-listed Clinic in Melbourne?

Our Story

The Australasian Leukaemia & Lymphoma Group (ALLG) is the only not-for-profit, investigator run clinical research group in Australia and New Zealand dedicated to finding new ways to treat blood cancers such as leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The ALLG membership includes more than 750 doctors, nurses, scientists and professional staff across Australia and New Zealand, all of whom are looking for ways to better treat blood cancers through clinical research. By conducting national and international collaborative clinical trials at sites across Australia and New Zealand, ALLG researchers are helping to make new and more effective treatments available to people suffering from blood cancers. For patients, this means an improved chance of cure, and better quality of life.